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The NFkB/Rel family of proteins play critical roles in
a variety of cellular processes. Thus, their physiolog-
ical activation is tightly controlled. Recently, the
NFkB2/p100 precursor has been characterized as
the fourth IkB type of suppressor for NFkB. However,
the molecular mechanism(s) underlying regulated
destruction of NFkB2 remains largely unknown.
Here, we report that, unlike other IkBs, ubiquitination
and destruction of NFkB2 are governed by SCFFbw7
in a GSK3-dependent manner. In Fbw7/ cells,
elevated expression ofNFkB2/p100 leads to a subse-
quent reduction in NFkB signaling pathways and
elevated sensitivity to TNFa-induced cell death.
Reintroducing wild-type Fbw7, but not disease-
derivedmutant formsof Fbw7, rescuesNFkBactivity.
Furthermore, T cell-specific depletion of Fbw7 also
leads to reduced NFkB activity and perturbed T cell
differentiation. Therefore, our work identifies Fbw7
as a physiological E3 ligase controlling NFkB20s
stability. It further implicates that Fbw7 might exert
its tumor-suppressor function by regulating NFkB
activity.
INTRODUCTION
The NFkB signaling pathway plays pivotal roles in many funda-
mental cellular processes, including the control of cell survival,
tumor invasion, drug resistance, and stress response (Baker
et al., 2011; Ben-Neriah and Karin, 2011). Therefore, the physio-
logical activation of the NFkB signaling pathway is tightly
controlled in vivo (Hoffmann and Baltimore, 2006; Wertz and
Dixit, 2010). Under nonstimulating conditions, NFkB is normally
sequestered in the cytoplasm through tight association with an
NFkB-inhibitory protein, IkB (Oeckinghaus et al., 2011; Smale,
2011). Upon stimulation by various cytokines, activation of the434 Cell Reports 1, 434–443, May 31, 2012 ª2012 The AuthorsIkB kinase (IKK) complex occurs, leading to phosphorylation
and subsequent ubiquitin-mediated degradation of IkB by
SCFb-TRCP (Shirane et al., 1999; Spencer et al., 1999). This rapid
destruction of IkB allows NFkB to translocate into the nucleus
and activate the expression of a wide spectrum of target genes
(Ben-Neriah and Karin, 2011; Karin and Ben-Neriah, 2000).
Moreover, SCFb-TRCP also governs the processing of the
NFkB1/p105 and NFkB2/p100 precursor proteins into the p50
and p52 active forms, respectively, which ultimately leads to
the full activation of the canonical and noncanonical NFkB
pathways (Wertz andDixit, 2010). However, themolecular mech-
anism underlying the regulated destruction of NFkB2, a recently
identified IkB type of suppressor (Basak et al., 2007; Legarda-
Addison and Ting, 2007), remains yet unknown.
Fbw7, also known as Fbxw7, forms an SCF type of ubiquitin
ligase complex that targets various oncogenic proteins for ubiq-
uitination (Cardozo and Pagano, 2004; Welcker and Clurman,
2008). In keeping with Fbw7’s antitumor activity, Fbw7 is
frequently inactivated by mutation, deletion, or promoter hyper-
methylation in multiple neoplasms (Welcker and Clurman, 2008).
Even though Fbw7’s known substrates are well documented for
their roles in cancer development and progression, the exact
molecular mechanisms by which Fbw7 suppresses cancer
formation have not yet been fully elucidated. In this regard, iden-
tification of novel Fbw7 ubiquitin substrate(s) might help to better
characterize its tumor suppressor functions.
RESULTS
Identification of NFkB2 as a Specific Fbw7-Interacting
Protein
We developed a mass-spectrometry-based analysis to perform
a nonbiased search for Fbw7 substrates. To achieve this goal,
we infected Fbw7/ DLD1 colon cancer cells with lentiviruses
encoding wild-type (WT) Fbw7 or various T cell acute lympho-
blastic leukemia (T-ALL) disease-derived mutant forms of
Fbw7 (Maser et al., 2007) (Figures 1A and S1A). Reintroduction
of WT Fbw7, but not various mutant forms of Fbw7, led to effi-






Figure 1. Identification of NFkB2 as a Specific Fbw7-Interacting Protein
(A) Immunoblot (IB) analysis of whole-cell lysates (WCLs) derived from Fbw7/ DLD1 cells infected with Fbw7-expressing lentiviral constructs.
(B) IB analysis of WCLs and HA-immunoprecipitates (IPs) derived from Fbw7/ DLD1 cells infected with the HA-R465H-Fbw7-expressing lentiviral construct.
(C) The list of top candidates identified in the two mass spectrometry screenings searching for putative SCFFbw7 ubiquitin substrates.
(D) IB analysis of WCLs and IPs derived from 293T cells transfected with HA-b-TRCP1 together with Flag-NFkB1 or Flag-NFkB2 construct.
(E) IB analysis of WCLs and IPs derived from 293T cells transfected with HA-Fbw7 together with Flag-NFkB1 or Flag-NFkB2 construct.
(F) IB analysis of WCLs and anti-NFkB2 IPs derived from HeLa cells. Mouse IgG was used as a negative control.
(G) IB analysis of WCLs and IPs derived from 293T cells transfected with Flag-NFkB2 together with a panel of GST-tagged F-box proteins.
(H) IB analysis of WCLs and IPs derived from 293T cells transfected with Flag-NFkB2 together with the indicated Myc-tagged Cullin family of proteins.
(I and J) IB analysis of WCLs and IPs derived from 293T cells transfected with Flag-NFkB2 together with Myc-Skp1 (I) or Myc-Rbx1 (J).
See also Figure S1.c-Myc, and Mcl-1 (Figure 1A). The failure of mutant Fbw7 to
promote the destruction of cyclin E is largely due to the reduced
interaction between the substrate and the Fbw7 mutants
(Figures 1B and S1B). This observed difference in binding affinity
serves as the rationale for our mass-spectrometry-based
screening: putative Fbw7 substrates should display stronger
interactions to WT Fbw7 than to the mutant forms of Fbw7.Moreover, the successful identification of c-Myc, a well-charac-
terized Fbw7 substrate (Welcker et al., 2004; Yada et al., 2004),
as well as EBNA1BP2, a recently identified Fbw7 phosphode-
gron-containing protein (Welcker et al., 2011), validated our
screening strategy (Figure 1C).
Notably, the NFkB2/p100 precursor protein was identified as
one of the top Fbw7 substrate candidates in both screensCell Reports 1, 434–443, May 31, 2012 ª2012 The Authors 435










Figure 2. Fbw7 Negatively Regulates the Stability of NFkB2
(A) IB analysis of WT or Fbw7/ DLD1 and HCT116 cells.
(B–E) Real-time RT-PCR analysis examining the relative mRNA expression levels of NFkB1 (B), NFkB2 (C), IkBa (D), and RelB (E) in WT and Fbw7/ DLD1 cells.
The error bars represent 1 SD, and the p value was generated with the use of the Student’s t test. *: p < 0.01, n = 3.
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(Figure 1C). Although both NFkB1 (Cohen et al., 2004) and
NFkB2 (Xiao et al., 2001) were found to interact with b-TRCP1
(Figure 1D), only NFkB2, but not NFkB1, specifically interacts
with Fbw7 (Figure 1E). The detected interaction between endog-
enous Fbw7 and NFkB2 further implicates Fbw7 as a physiolog-
ical interactor of NFkB2 (Figure 1F). Moreover, NFkB2 interacts
only with b-TRCP1 and Fbw7 among a panel of F-box proteins
examined (Figure 1G). We further showed that NFkB2 specifi-
cally interacts with Cullin-1 but not other Cullin family members
(Figure 1H). Furthermore, we detected NFkB20s interaction
with Skp1 (Figure 1I) and Rbx1 (Figure 1J). These results collec-
tively showed that NFkB2 is a physiological interactor of
SCFFbw7, which prompted us to further investigate whether
NFkB2 is a downstream ubiquitin substrate of Fbw7.
Fbw7 Negatively Regulates the Stability of NFkB2
Consistent with this notion, we found that in both HCT116 and
DLD1 colon cancer cell lines, depletion of endogenous Fbw7
(Rajagopalan et al., 2004) leads to a significant increase in the
expression of NFkB2/p100, as well as a moderate increase in
the processed p52 protein (Figures 2A and S2A). Consistent
with a posttranslational mode of regulation, no significant
change in NFkB2 mRNA levels was observed after depletion of
Fbw7 (Figure 2C), while the half-life of NFkB2 was significantly
extended in Fbw7/ DLD1 cells (Figure 2F). Furthermore,
MG132 treatment in WT DLD1 cells led to a significant increase
in NFkB2 abundance (Figure 2G), indicating the involvement of
the 26S proteasome in regulating NFkB2 protein abundance.
In agreement with NFkB2 as a suppressor of NFkB signaling
(Basak et al., 2007; Legarda-Addison and Ting, 2007), elevated
expression of NFkB2 in Fbw7/ cells resulted in decreased
protein abundance ofmanyNFkBdownstream targets, including
NFkB1 and IkBa (Basak et al., 2007; Lawrence et al., 2005) (Fig-
ure 2A). Importantly, we also detected reduced mRNA expres-
sion of various NFkB transcriptional targets, including NFkB1
(Figure 2B), IkBa (Figure 2D), and RelB (Figure 2E), supporting
the idea that depletion of Fbw7 leads to decreased NFkB
signaling.
To exclude the possible off-target effects associated with
chronic ablation of Fbw7, we further showed that acute depletion
of Fbw7 (Figures 2H, 2I, and S2C), but not other E3 ligases, such
as Skp2 or Cdh1, led to increased p100 expression (Figure 2H).
Although depletion of endogenous b-TRCP1 also led to elevated
NFkB2, the elevation is mainly due to the blockage of NFkB2
processing to p52 (Figure 2H) (Fong and Sun, 2002; Xiao et al.,
2001). More importantly, reintroducingWT Fbw7, but not mutant(F) WT or Fbw7/ DLD1 cell lines were treated with 20 mg/ml cycloheximide. At
indicated antibodies.
(G) IB analysis of WT or Fbw7/ DLD1 cells.
(H) IB analysis of HeLa cells transfected with the indicated siRNA oligonucleotid
(I) IB analysis of T98G cells infected with the indicated shRNA lentiviral vectors.
(J) IB analysis of Fbw7/ DLD1 cells infected with the indicated Fbw7-expressi
(K) IB analysis of WCLs and IPs derived from 293T cells transfected with Flag-N
(L) IB analysis of HeLa cells infected with the indicated lentiviral shRNA construc
(M and N) IB analysis of WCLs derived from WT or Fbw7/ DLD1 cells stimulate
time periods.
See also Figure S2.forms of Fbw7, into Fbw7/ DLD1 cells led to efficient destruc-
tion of NFkB2 (Figure 2J). Similar to cyclin E (Figure 1B), NFkB2
specifically interacts with the WT form, but not the mutant
forms, of Fbw7 (Figure 2K). In further support of NFkB2 being
a bona fide SCFFbw7 ubiquitin substrate, depletion of endoge-
nous Cullin-1 led to a significant increase in NFkB2 abundance
(Figures 2L and S2D).
However, it remained unclear under which physiological
conditions Fbw7 promotes the destruction of NFkB2. Next, we
continued to explore whether cytokines that can activate NFkB
signaling could also trigger Fbw7-dependent destruction of
NFkB2. Consistent with recent reports (Saitoh et al., 2003;
Sanz et al., 2010), we found that stimulation with the tumor
necrosis factor-like weak inducer of apoptosis (TWEAK) could
lead to an efficient degradation of IkBa and NFkB2, followed
by a recovery in later time points (Figure 2M). Importantly,
in Fbw7/ cells, SCFb-TRCP-mediated destruction of IkBa
remained relatively unaffected while the timely destruction of
NFkB2 was significantly impaired (Figure 2M). It is notable that
the recovery of IkBa expression in later time points was slightly
delayed in Fbw7/ cells, indicating a possible reduction of the
NFkB activity, as IkBa itself is a target of NFkB (Figure 2M).
Furthermore, TNFa-mediated timely destruction of NFkB2 is
also impaired in Fbw7/ cells (Figure 2N). These results
together emphasize the notion that SCFFbw7 is the physiological
E3 ligase that governs the destruction of NFkB2 upon stimulation
with various physiologic stimuli, including TWEAK and TNFa.
Fbw7 Promotes NFkB2 Ubiquitination and Destruction
in a GSK3-Dependent Manner
A close examination of the NFkB2 primary protein sequence
reveals that NFkB2 contains two evolutionally conserved puta-
tive degrons that closely resemble other known Fbw7 substrates
(Figure 3A). Importantly, in vivo phosphorylation of Ser707,
Ser711, and Thr759 was detected by mass spectrometry
analysis (Figure S3H). Furthermore, the ScanSite program
predicts that themarked Ser/Thr residues within the two putative
degrons are potential GSK3 sites. Consistent with this predic-
tion, GST-NFkB2 is efficiently phosphorylated by GSK3 in vitro
(Figure S3A). Although mutation of the S707/S711 and/or T759
sites led to reduced GSK3-mediated phosphorylation in vitro,
there is still residual phosphorylation even in the 3XA (S707A/
S711A/T759A) mutant form of GST-NFkB2 (Figure S3A). This
indicates that GSK3 might phosphorylate NFkB2 at other sites.
However, mutation of the Ser707 and Ser711 sites, but not of
Thr759, led to the abolishment of GSK3-induced interactionthe indicated time points, WCLs were prepared and IBs were probed with the
es.
ng lentiviral vectors.
FkB2 together with the indicated Fbw7 encoding constructs.
ts.
d with TWEAK (M) or TNFa (N) and harvested after stimulation at the indicated







Figure 3. Fbw7 Promotes NFkB2 Ubiquitination and Destruction in a GSK3 Phosphorylation-Dependent Manner
(A) Sequence alignment of NFkB2 with the consensus Fbw7 phosphodegrons. The putative Fbw7 phosphodegron sequence present in NFkB2 is conserved
across different species.
(B) IB analysis showing the recovery of HA-Fbw7 bound to the indicated GST-NFkB2 proteins (with GST as a negative control) after incubation with GSK3.
Ponceau S staining was performed to indicate equal loading of the indicated GST-fusion proteins.
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betweenGST-NFkB2 and Fbw7 in vitro (Figure 3B). Consistently,
mutation of S707/S711 led to a complete loss of in vivo interac-
tion between NFkB2 and Fbw7, while mutation of T759 only
moderately reduced this interaction (Figure 3C). Importantly,
pharmacological inhibition of GSK3 blocked the interaction
between HA-Fbw7 and NFkB2 in vivo (Figure 3D), leading to
elevated expression of NFkB2 (Figure S3C). Furthermore, deple-
tion of endogenous GSK3a/b resulted in elevated NFkB2 abun-
dance (Figure 3E), supporting GSK3 as the upstream modifying
kinase that governs NFkB2 stability. In keeping with this notion,
ectopic expression of Fbw7 and GSK3, but not other examined
kinases, promoted rapid disappearance of WT NFkB2 (Figures
3F, 3G, and S3B), which may be largely due to decreased
NFkB2 half-life (Figure 3H). Consistent with this finding, the
phospho-mimetic (S707D/S711D) mutant form of NFkB2
exhibited a shortened half-life (Figure S3F). On the other hand,
the S707A/S711A or 3XA mutant form of NFkB2, which failed
to interact with Fbw7 (Figure 3C), was resistant to Fbw7- and
GSK3-mediated destruction (Figures 3G and 3H).
Moreover, Fbw7- and GSK3-mediated NFkB2 destruction
was blocked by MG132 (Figure S3D). Interestingly, although
both NFkB1 and NFkB2 could be processed by b-TRCP1 (Wertz
and Dixit, 2010), only NFkB2 contains the Fbw7-recognizable
degron. As a result, NFkB2, but not NFkB1, could be targeted
for destruction by Fbw7 in a GSK3-dependent manner (Fig-
ure 3F). Furthermore, T-ALL-derived Fbw7 mutants failed to
promote the destruction of NFkB2 (Figures 3I and 3J), high-
lighting the possible clinical relevance between misregulation
of NFkB and mutation of the Fbw7 tumor suppressor. More
importantly, Fbw7 promotes NFkB2 ubiquitination in a GSK3-
dependent manner both in vivo (Figure 3K) and in vitro
(Figure S3G).
As processing of p100/NFkB2 to p52 by SCFb-TRCP is critical
for activation of the noncanonical NFkB signaling pathway
(Xiao et al., 2001), it is important to further understand whether
Fbw7 could affect NFkB2 processing. Interestingly, neither
mutating the identified degron (Ser707/Ser711) (Figure S4A)
nor depletion of Fbw7 notably affected the processing of
NFkB2 (Figure S4A). These results indicate that Fbw7 is involved
mainly in regulating NFkB2 stability, but not in NFkB2 process-
ing. To obtain a better understanding for the role of Fbw7 in regu-
lating NFkB2 stability and/or processing, we utilized NFkB1/2(C) IB analysis of WCLs and IPs derived from 293T cells transfected with HA-Fbw
(D) IB analysis of WCLs and IPs derived from 293T cells transfected with HA-Fb
DMSO as a negative control) was added for 8 hr before harvesting.
(E) IB analysis of HeLa cells transfected with the indicated siRNA oligos.
(F andG) IB analysis of 293T cells transfectedwith Flag-NFkB1 or the indicated NF
HA-GSK3.
(H) 293T cells were transfected with the indicated Flag-NFkB2 constructs togeth
cells were split into 60 mm dishes, and after another 20 hr, they were treated w
prepared and IBs were probed with the indicated antibodies.
(I) IB analysis of WCLs and IPs derived from 293T cells transfected with Flag-NF
(J) Fbw7/DLD1 cells were infected with Fbw7-expressing lentiviral constructs a
Afterwards, cells were split into 60 mm dishes, and after another 20 hr, they were
were prepared and IBs were probed with the indicated antibodies.
(K) Fbw7 promotes the in vivo ubiquitination of NFkB2. IB analysis of WCLs and
together with the HA-Fbw7 and HA-GSK3 plasmids, and Myc-Ub.
See also Figures S3 and S4.and NFkB2/1 chimera proteins (Figure S4B) (Heusch et al.,
1999). We found that, in terms of processing efficiency, the
NFkB2/1 chimera protein behaves similarly to NFkB1, while the
NFkB1/2 chimera protein behaves like NFkB2 (Figure S4C), sug-
gesting that the C terminus of NFkB1 versus NFkB2 determines
the processing efficiency (Heusch et al., 1999). On the other
hand, ectopic expression of Fbw7 and GSK3 leads to enhanced
destruction of NFkB2 (and NFkB1/2), but not of NFkB1 (or
NFkB2/1) (Figure S4C). These data altogether indicate that
Fbw7 is involved primarily in governing the stability of, but not
the processing of, NFkB2.
NFkB2 was found to be frequently mutated in human cancers
(Chang et al., 1995). Interestingly, the mutant NFkB2 proteins
lose the Fbw7-recognizable phosphodegron (Ser707/Ser711)
located at the C terminus of NFkB2 (Figure S4D), indicating
that these mutants are likely to evade the Fbw7-mediated ubiq-
uitination and destruction pathway. However, as most of the
mutations have disrupted ankyrin-repeat motifs, they may not
possess the IkB-type suppressive function anymore, thereby
leading to elevated NFkB signaling in tumors.
Loss of Fbw7 Leads to Elevated Expression of NFkB2,
which Subsequently Inhibits NFkB Activity
Next, we continued to explore how Fbw7 regulates the activity of
the NFkB signaling pathway by modulating NFkB2 abundance.
As illustrated in Figures 4A, 4B, and S5A–S5C, we observed
that the activity of NFkB-responsive promoters was decreased
in Fbw7/ colon cancer cell lines relative to their WT counter-
parts. Furthermore, in agreement with previous reports (Basak
et al., 2007; Legarda-Addison and Ting, 2007), depletion of
endogenous NFkB2 led to increased NFkB signaling, as evi-
denced by elevated 3XkB luciferase reporter activity, whereas
reintroducing WT or S707A/S711A NFkB2 in NFkB2/ mouse
embryonic fibroblasts (MEFs) led to reduced reporter activity
(Figures 4C and 4D). These results supported the notion that
NFkB2 behaves as an endogenous suppressor of the NFkB
signaling pathway and that Fbw7 may govern the activation of
the NFkBpathway by directly regulating NFkB2 stability. Consis-
tent with this hypothesis, we further demonstrated that, similar to
Fbw7-depletion-induced elevation of NFkB2 expression (Fig-
ure 2A), ectopic expression of WT or S707A/S711A NFkB2 in
WT DLD1 cells could also suppress the activity of the NFkB7 together with the indicated Flag-NFkB2-encoding constructs.
w7 and Flag-NFkB2. Where indicated, 25 mM of the GSK3b inhibitor VIII (with
kB2 constructs together with HA-Fbw7 plasmids in the presence or absence of
er with the HA-Fbw7 and HA-GSK3 plasmids. Twenty hours after transfection,
ith 20 mg/ml cycloheximide (CHX). At the indicated time points, WCLs were
kB2 together with the indicated Fbw7 encoding constructs.
nd selected with 1 mg/ml puromycin for 72 hr to eliminate the noninfected cells.
treated with 20 mg/ml cycloheximide (CHX). At the indicated time points, WCLs
IPs derived from 293T cells transfected with indicated Flag-NFkB2 constructs
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signaling pathway (Figures 4E and 4F). More importantly, reintro-
ducing WT Fbw7, but not mutant forms of Fbw7 that fail to
promote the destruction of NFkB2 (Figures 3I and 3J), into
Fbw7/ DLD1 cells could rescue the activity of NFkB to levels
similar to those ofWTDLD1 cells (Figures 4G and 4H). In keeping
with these findings, the induction of various endogenous NFkB
targets by the NFkB agonist TNFa was significantly delayed in
the Fbw7/ cells compared to their WT counterparts (Figures
4I–4K and S5D). More importantly, reintroducing WT Fbw7, but
not mutant Fbw7, rescued the deficient NFkB activation in
Fbw7/ cells (Figures 4L, 4M, and S5F), illustrating that Fbw7
is a physiological upstream regulator of the NFkB signaling
pathway.
Importantly, reduced NFkB signaling was observed after
depletion of Fbw7 in WT, but not NFkB2/, MEFs (Figures
S5G and S5H), indicating a significant role for NFkB2 in Fbw7-
mediated regulation of NFkB activity. However, it remains
unclear whether other Fbw7 substrates could also affect the
NFkB signaling pathway (Keller et al., 2010). Notably, depletion
of c-Myc (Figures S5I and S5J) or Mcl-1 (Figure S5K) did not
cause any noticeable change in NFkB activity. These results indi-
cate that NFkB2, but not other known Fbw7 substrates, is the
major route through which Fbw7 exerts its regulatory role toward
the NFkB signaling pathway. Importantly, results obtained from
theT cell-specific knockoutmousemodel further support a phys-
iological role of Fbw7 in governing NFkB2 stability (see Extended
Results).
Activation of NFkB signaling cascades has been previously
shown to protect against TNFa-induced cell death (Vallabhapur-
apu and Karin, 2009). In agreement with a previous report (Wang
et al., 2002), depletion of NFkB2 led to acquired resistance to
TNFa-induced cell death, while reintroducing WT NFkB2, and
to a much greater degree, the nondegradable NFkB2, could
fully restore TNFa sensitivity (Figure 4N). More interestingly,
compared to their WT counterparts, Fbw7/ cells were much
more sensitive to TNFa-induced cellular death (Figure 4O). Rein-
troduction of WT Fbw7, but not the T-ALL-derived mutant forms
of Fbw7, into Fbw7/ cells successfully restored the activation
of the NFkB pathway (Figures 4G and 4H) and resulted in
acquired resistance to TNFa (Figure 4O). These results estab-
lished the causal relationship between Fbw7 genetic status
and TNFa sensitivity and further implicate TNFa as an efficientFigure 4. Loss of Fbw7 Leads to Elevated Expression of NFkB2, which
(A and B) Normalized luciferase activities of WT and Fbw7/ DLD1 cells transfec
interleukin 6 promoter. In both cases, the same reporter construct with the NFkB
Where indicated, cells were treated with the NFkB agonist TNFa before harvesti
(C and D) Normalized luciferase activities of WT and NFkB2/ MEFs transfected
NFkB-responsive reporter. Where indicated, cells were treated with the NFkB ag
(E and F) Normalized luciferase activities of WT and Fbw7/ DLD1 cells transfec
3XkB NFkB-responsive reporter. Where indicated, cells were treated with the NF
(G andH) Normalized luciferase activities ofWT and various engineered Fbw7/D
indicated, cells were treated with the NFkB agonist TNFa (G) or IL-1b (H) before
(I–K) RT-PCR was performed to monitor the changes in IkBa (I), ICAM1 (J), and
stimulated with 10 ng/ml TNFa for the indicated time period.
(L andM) RT-PCRwas performed to analyze the induction of NFkB signaling pathw
to GAPDH mRNA, in the indicated WT and various engineered Fbw7/ DLD1 c
(N and O) Viability of the indicated cell lines after exposure to TNFa.
Data are presented as mean ± SD, n = 3. See also Figures S5, S6, and S7.therapeutic option for targeted treatment of Fbw7-deficient
tumors with alleviated NFkB signaling activity.
DISCUSSION
Our study identified Fbw7 as a negative upstream regulator for
NFkB2 abundance. We further showed that loss of Fbw7 led to
elevated expression ofNFkB2, a reported IkB-type of suppressor
(Basak et al., 2007), and subsequent suppression of NFkB
signaling even when there is a reduced expression of IkBa. This
is because the total abundance of IkB-type suppressors
including both NFkB2 and IkBa remains at high levels to actively
suppress NFkB. In this scenario, IkBa, a well-characterized tran-
scriptional target of NFkB, functions mainly as a read-out for the
reducedNFkBactivity observed in the Fbw7-compromised cells.
We further defined GSK3 as the upstream modifying enzyme
that phosphorylates NFkB2 to trigger Fbw7-mediated ubiquiti-
nation and subsequent destruction. Interestingly, we observed
a significant elevation of RelB protein abundance in Fbw7/
cells (Figures 2A and 2J) even though the RelB mRNA levels
were reduced (Figure 2E). However, RelB abundance was not
regulated by the Fbw7/GSK3 axis (Figure S3E), indicating that
RelB may not be a direct Fbw7 substrate (Fusco et al., 2008).
In summary, unlike the NIK/IKKa signaling pathway that triggers
NFkB2 processing, we identified GSK3 as an unique upstream
regulatory signaling that triggers the destruction of NFkB2, but
not NFkB1 (Figure S7A). Notably, processing of NFkB2 leads
to the production of p52, which subsequently activates the non-
canonical NFkB signaling pathway. On the other hand, degrada-
tion of NFkB2 serves mainly to unlock the IkB-type suppressive
function of NFkB2, leading to elevated canonical NFkB signaling.
However, there is no activation of the noncanonical NFkB
signaling pathway in this setting (Figure S7A).
Therefore, it is possible that in different cellular contexts, or in
response to different upstream stimuli, cells may choose to
process or degrade NFkB2, leading to the differential activation
of the canonical or the noncanonical NFkB signaling pathway
(Figure S7B). Furthermore, as mutations in NFkB2 have been
identified in human cancers (Wang et al., 2002), our results indi-
cate that aberration in the Fbw7/GSK3 regulatory axis might lead
to misregulated NFkB2 expression, which contributes to patho-
logical conditions associated with aberrant NFkB signaling.Subsequently Inhibits NFkB Activity
ted with artificial (A) or naturally occurring (B) NFkB-responsive reporter. IL-6,
site mutated (Mut-Luc) was used as a negative control for the luciferase assay.
ng for luciferase assay.
with indicated NFkB2-expressing constructs together with the artificial 3XkB
onist TNFa (C) or IL-1b (D) before harvesting for luciferase assay.
ted with the indicated NFkB2-expressing constructs together with the artificial
kB agonist TNFa (E) or IL-1b (F) before harvesting for luciferase assay.
LD1 cells transfectedwith the artificial 3XkBNFkB-responsive reporter. Where
harvesting for luciferase assay.
RelB (K) mRNA levels, normalized to GAPDH mRNA, in indicated cell lines
ay bymonitoring the changes in IkBa (L) andRelB (M)mRNA levels, normalized
ell lines stimulated with 10 ng/ml TNFa for the indicated time period.
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EXPERIMENTAL PROCEDURES
In Vitro Kinase Assay
GSK3 was purchased from New England Biolabs. The in vitro kinase reaction
was performed according to the manufacturer’s instructions. In brief, 5 mg
of the indicated GST fusion proteins was incubated with purified active
GSK3 in the presence of 5 mCi [g-32P] ATP and 200 mM cold ATP in the
kinase reaction buffer for 20 min. The reaction was stopped by the addition
of SDS-containing lysis buffer, resolved on SDS-PAGE, and detected by
autoradiography.
In Vitro NFkB2 Binding Assay
Binding to immobilized GST proteins was performed as described previously
(Wei et al., 2004). Where indicated, the GST-NFkB2 proteins were incubated
with GSK3 in the presence of 0.2 mM ATP for 1 hr prior to the binding assays.
Mice
Generation of conditional Fbw7 knockout mice (Lck-Cre/Fbw7F/F) was
described previously (Matsuoka et al., 2008; Onoyama et al., 2007). The
CD4/CD8 FACS analysis was performed as described previously (Tucker
et al., 2007). All mice experiments were approved by the Kyushu University
Animal Care and Use Committee, and the experiments were performed
according to the relevant regulatory standards.
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